Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Bone Marrow Transplant ; 40(9): 831-5, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17724443

ABSTRACT

Cryopreservation and thawing of haematopoietic stem cells are associated with cell loss and infusion-related toxicities. We analysed viability, total nucleated cell (TNC) and CD34+ cell recovery, and infusion-related toxicities of 952 thawed and washed products. Mean TNC and CD34+ viable cells recoveries were 55.9+/-18.6 and 98.0+/-36.5%, respectively. Mean cell viability was 68.25+/-18.9%. TNC recovery was correlated with viability but independent of the initial nucleated cell concentration. No difference in TNC recovery or viability was observed according to underlying diseases, except for myeloma, for which these variables were significantly lower (P<0.05). CD34+ cell recovery was not correlated with viability or CD34+ initial count and was similar for all diseases. Cryostorage duration was not associated with cell loss. Immediate adverse events occurred in 169 patients (19%) and were moderate (grade I or II) for the majority of patients. Clinical toxicity was associated with a higher infused cell number and the presence of clumps in infused bags. The washing procedure of cell products lead to a low rate of adverse events, but patients transplanted with high cell numbers or bags in which clumps were identified are predisposed to such complications.


Subject(s)
Cryopreservation/methods , Hematopoietic Stem Cells/cytology , Peripheral Blood Stem Cell Transplantation/adverse effects , Antigens, CD34 , Cell Count , Cell Survival , Hematologic Diseases/complications , Hematologic Diseases/therapy , Humans , Neoplasms/complications , Neoplasms/therapy , Peripheral Blood Stem Cell Transplantation/methods , Retrospective Studies , Risk Factors , Transplantation, Autologous
2.
Rheumatology (Oxford) ; 46(5): 833-41, 2007 May.
Article in English | MEDLINE | ID: mdl-17255134

ABSTRACT

OBJECTIVES: A clinico-pathological study in diffuse systemic sclerosis (SSc) patients was performed to analyse whether the skin histological organization and the pro-fibrotic signals elicited by TGF-beta in fibroblasts vary according to the modified Rodnan skin score (mRSS). METHODS: Twenty-seven SSc patients underwent 45 skin biopsies with simultaneous measure of mRSS before or after treatment by immunosuppressive drugs, with or without autologous peripheral haematopoietic stem cell transplantation (HSCT). RESULTS: Double-blind optic microscopy analysis of the biopsies standard extracellular matrix stains allowed to define three histological subgroups: 6 with grade 1 weak fibrosis, 30 with grade 2 moderate fibrosis and 9 with grade 3 severe fibrosis. A significant (P < 0.0001) was identified between the grades of fibrosis and the mRSS. In skin fibroblast cultures, Smad3 phosphorylation levels, as well as mRNA steady-state levels of two transforming growth factor (TGF)-beta/Smad3 targets, COL1A2 and PAI-1, increased in parallel with the mRSS. When compared with pre-transplant values the degree of fibrosis observed after HSCT in the papillary and in the reticular dermis decreased in parallel with the fall in mRSS (n = 5 consecutive patients with repeated biopsies). CONCLUSIONS: The histological extent of skin fibrosis correlates closely with the mRSS. Both parameters appeared to regress after HSCT. The extent of TGF-beta signalling activation in SSc skin fibroblasts appears to parallel the severity of disease.


Subject(s)
Scleroderma, Diffuse/pathology , Severity of Illness Index , Skin/pathology , Adult , Aged , Biopsy , Cells, Cultured , Collagen/biosynthesis , Collagen/genetics , Collagen Type I , Combined Modality Therapy , Double-Blind Method , Female , Fibroblasts/metabolism , Fibrosis/metabolism , Fibrosis/pathology , Humans , Immunoenzyme Techniques , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Peripheral Blood Stem Cell Transplantation , Phosphorylation , Plasminogen Activator Inhibitor 1/biosynthesis , Plasminogen Activator Inhibitor 1/genetics , RNA, Messenger/genetics , Scleroderma, Diffuse/metabolism , Scleroderma, Diffuse/therapy , Signal Transduction , Skin/metabolism , Smad Proteins/metabolism , Smad3 Protein/metabolism , Transforming Growth Factor beta/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...